{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:47Z","timestamp":1790983127685,"version":"4.1.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403836"],"award-info":[{"award-number":["82403836"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elderly cancer patients, particularly those aged \u226590 years, are significantly underrepresented in clinical trials, leaving a critical evidence gap for this growing population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 90-year-old man with multiple comorbidities (coronary artery disease, hypertension, type 2 diabetes, hyperlipidaemia, hepatic steatosis, and hypothyroidism) and an ECOG performance status 2, who was diagnosed with hepatocellular carcinoma (HCC) in 2015. After initial microwave ablation in 2017 and for recurrence in 2021, he developed multifocal intrahepatic progression in January 2023 at age 97. Following progression on pembrolizumab monotherapy (100 mg q3w) and intolerance to lenvatinib combination, treatment was adapted to reduced-dose pembrolizumab (100 mg q3w) plus reduced-dose bevacizumab (3.75 mg\/kg q3w)\u2014approximately half and one-quarter of standard doses, respectively. He achieved partial response after three cycles with significant symptomatic improvement. As of March 2025 (age 99), he has completed 23 cycles with a progression-free survival of 15 months. He maintains functional independence, satisfactory symptom control (liver pain NRS 1\u20132), and only grade 1 fatigue, with no treatment-related hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To our knowledge, this is the oldest reported patient with HCC to receive combined immunotherapy and anti-angiogenic therapy. This case suggests that with carefully adapted dosing\u2014using approximately half-dose pembrolizumab and quarter-dose bevacizumab\u2014a nonagenarian with multiple comorbidities may achieve prolonged disease control, challenging the conventional \u2018one-size-fits-all\u2019 dosing paradigm and highlighting the feasibility of individualized treatment strategies in the oldest-old population with HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1833336","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:55:49Z","timestamp":1785905749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Adaptive dosing of immunotherapy plus anti-angiogenic therapy in a nonagenarian with hepatocellular carcinoma: a case report with 10-year survival"],"prefix":"10.3389","volume":"16","author":[{"given":"Pengfei","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The 983rd Hospital of the People\u2019s Liberation Army","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueguang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nijia","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The Second Medical Center of Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Medical Center of Chinese People's Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000525671","article-title":"Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in the IMbrave150 randomized clinical trial","volume":"11","author":"Li","year":"2022","journal-title":"Liver Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03417-3","article-title":"Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: A retrospective, multicenter, real-world cohort study","volume":"72","author":"Xiao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2024.2341723","article-title":"The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"24","author":"Han","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000535338","article-title":"A phase 3 study of pembrolizumab versus placebo for previously treated patients from Asia with hepatocellular carcinoma: Health-related quality of life analysis from KEYNOTE-394","volume":"13","author":"Qin","year":"2024","journal-title":"Liver Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.102153","article-title":"Start low, go slow, a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis","volume":"16","author":"Aleixo","year":"2025","journal-title":"J Geriatr Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1713151","article-title":"Survival benefits of different immunotherapies for hepatocellular carcinoma: A meta-analysis highlighting age, gender, etiology, and tumor burden","volume":"16","author":"Guan","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41698-025-00908-7","article-title":"Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma","volume":"9","author":"Ball","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40164-025-00636-5","article-title":"Targeting immune checkpoints in hepatocellular carcinoma therapy: Toward combination strategies with curative potential","volume":"14","author":"Tong","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001725","article-title":"Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study","author":"Tovoli","year":"2026","journal-title":"Hepatology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1833336\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:55:57Z","timestamp":1785905757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1833336\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1833336"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1833336","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1833336"}}